Revolution Medicines, Inc.

The company is a clinical-stage precision oncology company focused on developing new targeted therapies for cancers driven by RAS mutations. It uses advanced structure-based drug discovery, chemical biology, cancer pharmacology, and proprietary technologies to create small molecules for specific binding sites. The company's approach is guided by its understanding of genetic drivers and resistance mechanisms in cancer, informing both single-drug and combination treatment regimens. Its research and development pipeline includes RAS(ON) Inhibitors, which are designed to bind directly to active RAS variants. These inhibitors are intended for use alone, in combination with other RAS(ON) Inhibitors, or with other therapeutic agents. The RAS(ON) Inhibitors are based on a proprietary tri-complex technology platform, which allows for a distinct way to inhibit the active, GTP-bound form of RAS. The company is developing a portfolio of compounds that it believes were the first RAS(ON) Inhibitors to use this mechanism. It believes these direct RAS(ON) inhibitors suppress cell growth and survival and are less prone to adaptive resistance compared to RAS inhibitors that target the inactive, GDP-bound form of RAS (RAS(OFF) inhibitors). The company believes tailored RAS(ON) Inhibitors will be effective for various RAS-addicted cancers. For some patients, a broad-acting RAS(ON) multi-selective inhibitor like daraxonrasib (RMC-6236), designed to inhibit multiple oncogenic RAS variants, may provide the most benefit. In other situations, a RAS(ON) mutant-selective inhibitor, targeting a specific RAS mutation, may be optimal. The company also believes that combining daraxonrasib with a RAS(ON) mutant-selective inhibitor, with daraxonrasib as the foundation, could be beneficial. Additionally, combining its RAS(ON) Inhibitors with standard treatments, including immunotherapies or other new therapies, may be optimal in some cases.